Clareo Health | A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Histologically or cytologically confirmed Stage III B or Stage IV squamous non-small cell lung cancer (NSCLC)
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
No prior chemotherapy for squamous NSCLC
Adequate tissue for central IHC assay of Met receptor, and EGFR testing if EGFR status is unknown
Radiographic evidence of disease
You may not be if
Prior systemic treatment for Stage IIIB or IV squamous NSCLC
NSCLC with histology classified as adenocarcinoma, large cell, mixed adenosquamous, or NSCLC not otherwise specified (NOS)
Prior exposure to experimental treatment targeting either the HGF or Met pathway
Patients with tumors confirmed to have EGFR-activating mutations who are suitable for anti-EGFR therapy (e.g. gefitinib or erlotinib), as determined by the investigator
Uncontrolled brain metastases and treatment by neurosurgical resection or brain biopsy within 4 weeks prior to Day 1 of Cycle 1
History of another malignancy in the previous 3 years except for prior history of in situ cancer or basal or squamous cell skin cancer
Pregnant or lactating women
Uncontrolled diabetes
Impaired bone marrow, liver or renal function as defined by protocol
